Hart J A, Haynes B P, Park B K
Biochem Pharmacol. 1984 Oct 1;33(19):3013-9. doi: 10.1016/0006-2952(84)90602-6.
The pharmacological response to vitamin K has been determined by measuring prothrombin complex activity (P.C.A.) in male New Zealand White rabbits anticoagulated (P.C.A. less than 20%) with the long acting 4-hydroxycoumarin brodifacoum, at a dose (10 mg/kg) which produces maximum antagonism of vitamin K1. Thus, according to current concepts, this animal model may be used to assess vitamin K requirements in the absence of a functional vitamin K-epoxide reductase. After intravenous administration of vitamin K1 (1 mg/kg) P.C.A. reached a maximum (64 +/- 19%) at 3 hr and then declined at a rate which corresponds to complete inhibition of clotting factor synthesis. Vitamin K2 (1 mg/kg) stimulated clotting factor synthesis for 2 hr, while cis-vitamin K1, vitamin K3, vitamin K1 2,3-epoxide and oral administration of vitamin K1 were ineffective. Plasma concentrations of vitamin K1 fell steeply during the 12 hr following administration of a pharmacological dose, and then declined with a terminal half-life of 18.9 +/- 9.0 hr. Comparison of the pharmacodynamic and pharmacokinetic data indicated that plasma concentrations in the range 0.4-1.0 microgram/ml are required for clotting factor synthesis in the limiting situation of maximum antagonism of vitamin K by coumarin anticoagulants. These findings explain why frequent and repeated administration of vitamin K1 may be necessary during coumarin poisoning.
通过测量用长效4-羟基香豆素溴敌隆抗凝(凝血酶原复合物活性小于20%)的雄性新西兰白兔的凝血酶原复合物活性(P.C.A.),来确定对维生素K的药理反应。所用剂量(10mg/kg)可使维生素K1产生最大拮抗作用。因此,根据目前的概念,这种动物模型可用于评估在缺乏功能性维生素K-环氧化物还原酶的情况下维生素K的需求量。静脉注射维生素K1(1mg/kg)后,凝血酶原复合物活性在3小时时达到最大值(64±19%),然后以与凝血因子合成完全受抑制相对应的速率下降。维生素K2(1mg/kg)刺激凝血因子合成达2小时,而顺式维生素K1、维生素K3、维生素K1 2,3-环氧化物以及口服维生素K1均无效。给予药理剂量的维生素K1后12小时内,血浆中维生素K1浓度急剧下降,然后以18.9±9.0小时的终末半衰期下降。药效学和药代动力学数据的比较表明,在香豆素抗凝剂对维生素K产生最大拮抗作用的极限情况下,凝血因子合成需要血浆浓度在0.4 - 1.0微克/毫升范围内。这些发现解释了为什么在香豆素中毒期间可能需要频繁且重复地给予维生素K1。